Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
M & A Deals Diagnostics

Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio

  • Analysis

Executive Summary

Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.

You may also be interested in...



Qiagen CFO Sees COVID Diagnostics Volatility Continuing In 2022

Qiagen’s doubled-down focus on PCR technologies in late 2019 proved to be fortuitous, but future growth will come from many other drivers, says CFO Roland Sackers.

Qiagen Ready To Rival Abbott With Rapid, Portable Antigen COVID-19 Test

The diagnostics company said the test is scheduled for US launch in Q4 2020.

Qiagen Terminates Thermo Fisher Deal After Shareholders Reject Last Offer

Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.

Table

View full table

Topics

Related Companies

Tags:
M & A Deals Diagnostics
Latest Headlines

Oxford Biodynamics Releases EpiSwitch Prostate Cancer Test Early

Minute Insight: Enovis Buys Lima To Great Billion-Dollar Recon Business

Contingency Planning: Guidance Doc Details Handling Clinical Trials During Emergencies

ZimVie Wins Investigational Device Exemption For Disc Replacement Device, Plans To Begin Study

See All
UsernamePublicRestriction

Register

MT142830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By